Selected cyclic citrullinated peptides derived from the sequence of mutated and citrullinated vimentin (MCV) are targeted by different antibodies subclasses in patients with rheumatoid arthritis in Russian patients

Clinical and Experimental Rheumatology

Volumn 32, Issue 5, 2014, Pages 622-629

  Derganova, Olga ^a,b   Martinez Gamboa, Lorena ^a   Egerer, Karl ^a,c   Bang, Holger ^d   Fredenhagen, Gert ^d   Roggenbuck, Dirk ^e,f   Esaulenko, Igor ^b   Burmester, Gerd Rüdiger ^a   Chernykh, Tatiana ^b   Feist, Eugen ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b VORONEZH STATE MEDICAL UNIVERSITY NAMED AFTER N N BURDENKO   (Russian Federation)

^c Berlin Space Technologies GmbH   (Germany)

^d ORGenTec Diagnostika GmbH   (Germany)

^e Medipan GmbH   (Germany)

^f Lausitz University of Applied Sciences   (Germany)

Author keywords

Acpa; Citrullinated peptides; Modified vimentin; Rheumatoid arthritis

Indexed keywords

AUTOANTIGEN; CYCLIC CITRULLINATED PEPTIDE; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; EPITOPE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MUTATED AND CITRULLINATED VIMENTIN; PEPTIDE; RHEUMATOID FACTOR; UNCLASSIFIED DRUG; VIMENTIN; AUTOANTIBODY; BIOLOGICAL MARKER; CYCLOPEPTIDE;

ANTIBODY DETECTION; ANTIGEN RECOGNITION; ARTICLE; CITRULLINATED SITE; CONTROLLED STUDY; DISEASE CLASSIFICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PROTEIN STRUCTURE; RHEUMATOID ARTHRITIS; RUSSIAN (PEOPLE); SENSITIVITY AND SPECIFICITY; ADULT; AGED; ANTIBODY SPECIFICITY; ARTHRITIS, RHEUMATOID; BLOOD; CASE CONTROL STUDY; CLASSIFICATION; EPITOPE MAPPING; GENETICS; IMMUNOLOGY; MIDDLE AGED; PREDICTIVE VALUE; REPRODUCIBILITY; RUSSIAN FEDERATION; YOUNG ADULT;

ADULT; AGED; ANTIBODY SPECIFICITY; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; AUTOANTIGENS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; EPITOPES; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; RUSSIA; VIMENTIN; YOUNG ADULT;

EID: 84907582784     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. NIJENHUIS S, ZENDMAN AJ, VOSSENAAR ER, PRUIJN GJ, van VENROOIJ WJ: Autoantibodies to citrullinated proteins in rheumatoid arthritis: clinical performance and biochemical aspects of an RA-specific marker. Clin Chim Acta 2004; 350: 17-34.
2. SEBBAG M, MOINARD N, AUGER I et al.: Epitopes of human fibrin recognized by the rheumatoid arthritis-specific autoantibodies to citrullinated proteins. Eur J Immunol 2006; 36: 2250-63.
3. LUNDBERG K, KINLOCH A, FISHER BA et al.: Antibodies to citrullinated alpha-enolase peptide 1 are specific for rheumatoid arthritis and cross-react with bacterial enolase. Arthritis Rheum 2008; 58: 3009-19.
4. MENARD HA, LAPOINTE E, ROCHDI MD, ZHOU ZJ: Insights into rheumatoid arthritis derived from the Sa immune system. Arthritis Res 2000; 2: 429-32.
5. BURKHARDT H, SEHNERT B, BOCKERMANN R, ENGSTROM A, KALDEN JR, HOLMDAHL R: Humoral immune response to citrullinated collagen type II determinants in early rheumatoid arthritis. Eur J Immunol 2005; 35: 1643-52.
6. BANG H, EGERER K, GAULIARD A et al.: Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum 2007; 56: 2503-11.
7. SHI J, KNEVEL R, SUWANNALAI P et al.: Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci USA 2011; 108: 17372-7.
8. WEGNER N, LUNDBERG K, KINLOCH A et al.: Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of rheumatoid arthritis. Immunol Rev 2010; 233: 34-54.
9. ALETAHA D, NEOGI T, SILMAN AJ et al.: 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62: 2569-81.
10. ALETAHA D, NEOGI T, SILMAN AJ et al.: 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010; 69: 1580-8.
11. NEOGI T, ALETAHA D, SILMAN AJ et al.: The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. Arthritis Rheum 2010; 62: 2582-91.
12. COENEN D, VERSCHUEREN P, WESTHOVENS R, BOSSUYT X: Technical and diagnostic performance of 6 assays for the measurement of citrullinated protein/peptide antibodies in the diagnosis of rheumatoid arthritis. Clin Chem 2007; 53: 498-504.
13. SCHELLEKENS GA, de JONG BA, van den HOOGEN FH, van de PUTTE LB, van VENROOIJ WJ: Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998; 101: 273-81.
14. van VENROOIJ WJ, VOSSENAAR ER, ZENDMAN AJ: Anti-CCP antibodies: the new rheumatoid factor in the serology of rheumatoid arthritis. Autoimmun Rev 2004; 3 (Suppl. 1): S17-19.
15. PRUIJN GJ, WIIK A, van VENROOIJ WJ: The use of citrullinated peptides and proteins for the diagnosis of rheumatoid arthritis. Arthritis Res Ther 2010; 12: 203.
16. RANTAPAA-DAHLQVIST S, de JONG BA, BERGLIN E et al.: Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003; 48: 2741-9.
17. MATHSSON L, MULLAZEHI M, WICK MC et al.: Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides. Arthritis Rheum 2008; 58: 36-45.
18. WHITING PF, SMIDT N, STERNE JA et al.: Systematic review: accuracy of anti-citrullinated Peptide antibodies for diagnosing rheumatoid arthritis. Ann Intern Med 2010; 152: 456-64; W155-466.
19. WILLEMZE A, TROUW LA, TOES RE, HUIZINGA TW: The influence of ACPA status and characteristics on the course of RA. Nat Rev Rheumatol 2012; 8: 144-52.
20. PREVOO ML, van't HOF MA, KUPER HH, van LEEUWEN MA, van de PUTTE LB, van RIEL PL: Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
21. HOCHBERG MC, CHANG RW, DWOSH I, LINDSEY S, PINCUS T, WOLFE F: The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 1992; 35: 498-502.
22. STEINBROCKER O, TRAEGER CH, BATTERMAN RC: Therapeutic criteria in rheumatoid arthritis. J Am Med Assoc 1949; 140: 659-62.
23. AUGER I, BALANDRAUD N, RAK J, LAMBERT N, MARTIN M, ROUDIER J: New autoantigens in rheumatoid arthritis (RA): screening 8268 protein arrays with sera from patients with RA. Ann Rheum Dis 2009; 68: 591-4.
24. VERPOORT KN, CHEUNG K, IOAN-FACSINAY A et al.: Fine specificity of the anti-citrullinated protein antibody response is influenced by the shared epitope alleles. Arthritis Rheum 2007; 56: 3949-52.
25. IOAN-FACSINAY A, WILLEMZE A, ROBINSON DB et al.: Marked differences in fine specificity and isotype usage of the anti-citrullinated protein antibody in health and disease. Arthritis Rheum 2008; 58: 3000-8.
26. HILL JA, SOUTHWOOD S, SETTE A, JEVNIKAR AM, BELL DA, CAIRNS E: Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J Immunol 2003; 171: 538-41.
27. SIZOVA L: Diagnostic value of antibodies to modified citrullinated vimentin in early rheumatoid arthritis. Hum Immunol 2012; 73: 389-92.
28. SYVERSEN SW, GOLL GL, van der HEIJDE D et al.: Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a 10-year prospective study. Ann Rheum Dis 2010; 69: 345-51.
29. van der LINDEN MP, van der WOUDE D, IOAN-FACSINAY A et al.: Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis. Arthritis Rheum 2009; 60: 2232-41.
30. DEJACO C, KLOTZ W, LARCHER H, DUFTNER C, SCHIRMER M, HEROLD M: Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis. Arthritis Res Ther 2006; 8: R119.
31. BARTOLONI E, ALUNNO A, BISTONI O et al.: Diagnostic value of anti-mutated citrullinated vimentin in comparison to anti-cyclic citrullinated peptide and anti-viral citrullinated peptide 2 antibodies in rheumatoid arthritis: An Italian multicentric study and review of the literature. Autoimmun Rev 2012; 11: 815-20.
32. URSUM J, NIELEN MM, van SCHAARDENBURG D et al.: Antibodies to mutated citrullinated vimentin and disease activity score in early arthritis: a cohort study. Arthritis Res Ther 2008; 10: R12.
33. MJAAVATTEN MD, van der HEIJDE DM, UHLIG T et al.: Should anti-citrullinated protein antibody and rheumatoid factor status be reassessed during the first year of followup in recent-onset arthritis? A longitudinal study. J Rheumatol 2011; 38: 2336-41.
34. van de STADT LA, van der HORST AR, de KONING MH et al.: The extent of the anti-citrullinated protein antibody repertoire is associated with arthritis development in patients with seropositive arthralgia. Ann Rheum Dis 2011; 70:128-33.
35. van der WOUDE D, RANTAPAA-DAHLQVIST S, IOAN-FACSINAY A et al.: Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis. Ann Rheum Dis 2010; 69: 1554-61.
36. WILLEMZE A, BOHRINGER S, KNEVEL R et al.: The ACPA recognition profile and subgrouping of ACPA-positive RA patients. Ann Rheum Dis 2012; 71: 268-74.
37. KOKKONEN H, MULLAZEHI M, BERGLIN E et al.: Antibodies of IgG, IgA and IgM isotypes against cyclic citrullinated peptide precede the development of rheumatoid arthritis. Arthritis Res Ther 2011; 13: R13.
38. LAKOS G, SOOS L, FEKETE A et al.: Anti-cyclic citrullinated peptide antibody isotypes in rheumatoid arthritis: association with disease duration, rheumatoid factor production and the presence of shared epitope. Clin Exp Rheumatol 2008; 26: 253-60.
39. SUWANNALAI P, WILLEMZE A, van TOORN L et al.: The fine specificity of IgM anti-citrullinated protein antibodies (ACPA) is different from that of IgG ACPA. Arthritis Res Ther 2011; 13: R195.
40. MUSTILA A, KORPELA M, HAAPALA AM et al.: Anti-citrullinated peptide antibodies and the progression of radiographic joint erosions in patients with early rheumatoid arthritis treated with FIN-RACo combination and single disease-modifying antirheumatic drug strategies. Clin Exp Rheumatol 2011; 29: 500-5.
41. FEIST E, EGERER K, BURMESTER GR: [Autoantibody profile in rheumatoid arthritis]. Zeitschrift fur Rheumatologie 2007; 66: 212-4, 216-8.
42. AGRAWAL S, MISRA R, AGGARWAL A: Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA. Clinical rheumatology 2007; 26: 201-4.
43. KAYE JJ, FUCHS HA, MOSELEY JW, NANCE EP, Jr., CALLAHAN LF, PINCUS T: Problems with the Steinbrocker staging system for radiographic assessment of the rheumatoid hand and wrist. Invest Radiol 1990; 25: 536-44.